[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eccogene\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100615094","phase-2-a-study-of-a-thyroid-hormone-receptor-beta-isoform-thr-agonist-and-an-semicarbazide-sensitive-amine-oxidase-ssao-inhibitor-alone-and-in-combination-in-adults-with-presumed-metabolic-dysfunction-associated-steatohepatitis-mash-100615094",false,"NCT07288138","A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)","A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a THRβ Agonist (ECC4703), an SSAO Inhibitor (ECC0509), and Their Combination in Adults With Presumed MASH","Inclusion Criteria:\n\n1. Adults between 18 and 75 years of age, inclusive, who can provide written informed consent and comply with study procedures.\n2. Diagnosis of presumed MASH based on: liver biopsy within 180 days prior to screening showing an NAFLD activity score (NAS) of ≥3 and a fibrosis score (F) of F1-3 OR FibroScan® CAP \\>280 dB\u002Fm at screening with presence of metabolic risk factors.\n3. Evidence of hepatic steatosis confirmed by FibroScan® LSM \\> 7 kPa and \\\u003C 20 kPa and MRI-PDFF \\>8% at screening.\n4. BMI \\>25 kg\u002Fm\\^2 to \\\u003C50 kg\u002Fm\\^2 (non-Asian); BMI ≥23.0 to \\\u003C50.0 kg\u002Fm\\^2 (Asian).\n5. ALT ≥60 U\u002FL at the first screening visit and stability of ALT and AST levels during the screening period.\n6. Estimated glomerular filtration rate (eGFR) ≥60 mL\u002Fmin\u002F1.73m\\^2 (Chronic Kidney Disease Epidemiology Collaboration, \\[CKD-EPI\\]).\n7. Stable body weight (no \\>5% change) for at least 6 months prior to screening.\n8. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential).\n9. In the opinion of the investigator, able to participate safely and complete required MRI\u002Fbiomarker assessments.\n\nExclusion Criteria:\n\n1. Chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD)\u002FMASH, including alcoholic liver disease, autoimmune hepatitis, cholestatic disease, genetic liver diseases, or drug-induced liver injury.\n2. Presence of cirrhosis on liver histology according to the assessment of the central reader, and\u002For cross-sectional imaging evidence consistent with cirrhosis and\u002For portal hypertension (e.g, nodular liver contour; portosystemic collaterals, ascites, splenomegaly; known presence or history of esophageal varices; and\u002For elastography evidence consistent with cirrhosis).\n3. ALT and\u002For AST \\>5× Upper Limit of Normal (ULN) or ALP \\>2×ULN at screening.\n4. Clinically significant thyroid or adrenal dysfunction, including uncontrolled hypothyroidism, hyperthyroidism, or adrenal disorders.\n5. Type 1 diabetes, HbA1c \\>9.5%, or unstable type 2 diabetes requiring medication changes within 90 days.\n6. Use of medications that affect liver fat or fibrosis (e.g., Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) not on a stable dose, pioglitazone, obeticholic acid, high-dose vitamin E, hepatotoxic drugs) within protocol-specified washout periods.\n7. Significant alcohol use within 1 year prior to screening.\n8. Recent cardiovascular events, including myocardial infraction (MI), stroke, unstable angina, heart failure (New York heart association \\[NYHA III-IV\\]), or uncontrolled arrhythmia.\n9. Current or recent serious psychiatric illness, including psychosis, active suicidal ideation, or suicide attempt within 5 years.\n10. Pregnancy, breastfeeding, or conditions that increase risk or interfere with study procedures, including MRI contraindications or other investigator-determined safety concerns.","ALL","18 Years","75 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.",[27],"Metabolic Dysfunction-associated Steatohepatitis",[29,30,31,32],"Liver Disease","Nonalcoholic Steatohepatitis","ECC0509","ECC4703","RECRUITING","2026-06-04",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":37},"2025-12-15",{"date":41,"type":21},"2027-09-29",{"name":43,"class":44},"Eccogene","INDUSTRY",58,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100618627","phase-1-ecc4703-food-effect-and-relative-bioavailability-study-in-healthy-adult-participants-100618627","NCT07334080","ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants","A Phase I, Open-Label, Randomized, Single-Dose, Crossover Study to Evaluate Food Effect and Relative Bioavailability of ECC4703 Formulations (F0, F1, F2, and F3) in Healthy Adults","Inclusion Criteria:\n\n* Healthy male and female participants\n* Age of 18 to 65 years\n* BMI of 18.0 to 32.0 kg\u002Fm2 with a minimum body weight of 50.0 kg (110 lb) for males and 45.0 kg (99 lb) for females.\n* Female participants of childbearing potential must have negative serum pregnancy test at screening and a negative serum or urine pregnancy test prior to the first dose of study drug; use at least 1 highly effective method of contraception (e.g., hormonal contraception, intrauterine device, bilateral tubal occlusion, or vasectomized partner with confirmed success) during the study and for at least 90 days after the last dose of study drug; and refrain from egg donation or fertility treatments during the same period.\n* Female participants who are postmenopausal, confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence\n* Male participants agree to use contraception, or agree to practice true abstinence\n* Not taking any medication within 14 days (or at least 5 half-lives whichever is longer) prior to Day 1 dosing, with the exception of stable-dose contraception, stable-dose hormonal replacement therapy, paracetamol at up to 2 g\u002Fday; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments.\n* No clinically significant findings in physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, clinical laboratory evaluations, concomitant medications, or medical\u002Fpsychiatric history\n* Able to understand and sign and date informed consent\n\nExclusion Criteria:\n\n* Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 90 days after the study.\n* Concomitant participation in any investigational study of any nature\n* Blood loss of ≥470 mL for non-physiological reasons (i.e., trauma, blood collection, blood donation) within 3 months prior to the first dose of study drug, plasma donation within 2 weeks prior to the first dose, platelet donation within 6 weeks prior to the first dose, or plans to donate blood during this study or within 1 month after the last dose of study drug.\n* Clinically relevant acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic systems\n* Significant allergic reaction to active ingredients or excipients of the study drug\n* Regularly uses tobacco or nicotine products, including e-cigarettes (\\>5 times per week) or has stopped using regular tobacco or nicotine products within the past 2 months.\n* Unwilling to abstain from alcohol-containing products and\u002For xanthine\u002Fcaffeine-containing products, including any food and beverages, within 48 hours prior to admission to the CRU on Day -1.\n* Unwilling to abstain from grapefruit, grapefruit juice, and Seville oranges from 7 days prior to check-in on Day -1 until after their final follow-up visit.\n* Unable to refrain from the use of any over-the-counter medications, prescription medications, nutritional supplements, or herbal medicines during the study, except for stable-dose contraception, stable-dose hormonal replacement therapy, paracetamol at up to 2 g\u002Fday; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments.\n* Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study.\n* Has had clinically significant interventional therapies and\u002For hospitalization (surgery, paracentesis, etc.) within 6 months prior to the study, or plans to have any surgeries during the duration of the study.",true,"65 Years",{"count":56,"type":21},72,[58],"PHASE1","This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.",[61],"Metabolic Dysfunction-Associated Steatohepatitis","2026-01-14",{"date":64,"type":37},"2026-01-16",{"date":66,"type":21},"2026-01-10",{"date":68,"type":21},"2026-05",{"name":43,"class":44},1,""]